Keros Therapeutics, Inc. (NasdaqGM: KROS)
Health Care · Biotechnology · US
$11.12
-2.11% today · -27.3% 1Y
Keros Therapeutics, Inc. (NasdaqGM: KROS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $225.24M and employs 92 people.
Over the last twelve months the share price has lost 27.3%, trading between 9.69 and 22.55.
Tweenvest scores Keros Therapeutics, Inc. across four factors: quality 38/100, value 45/100. Its strongest factor is value.
KROS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $225.24M
- Revenue (TTM)
- $15.01M
- P/E
- —
- EPS
- -3.10
- Dividend yield
- —
- Beta (5Y)
- 1.12
- 52-week high
- $22.55
- 52-week low
- $9.69
- Avg volume (3M)
- —
- Shares outstanding
- 19.83M
- Employees
- 92
- Next earnings
- —
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
- ISIN
- US4923271013
- Founded
- 2015
- Listed since
- Apr 8, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Panacea Biotec LimitedNSEI: PANACEABIO | $228.42M | Rs359.05 | -3.64% |
| Lyell Immunopharma, Inc.NasdaqGS: LYEL | $226.92M | $8.30 | -10.37% |
| MacroGenics, Inc.NasdaqGS: MGNX | $226.14M | $3.48 | -1.97% |
| Evommune, Inc.NYSE: EVMN | $225.74M | $6.08 | -2.25% |
| HansBiomed CorporationKOSDAQ: A042520 | $225.02M | ₩21,250.00 | +19.52% |
| Beijing Biostar Pharmaceuticals Co., Ltd.SEHK: 2563 | $224.41M | HK$4.83 | +13.65% |
| Cartesian Therapeutics, Inc.NasdaqGM: RNAC | $222.68M | $6.60 | -10.33% |
| Genomictree Inc.KOSDAQ: A228760 | $222.35M | ₩12,200.00 | +10.91% |
Figures last refreshed Oct 4, 2026.